Exicure (XCUR) Stock Overview
Does not have significant operations. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
XCUR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeExicure, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.25 |
| 52 Week High | US$11.86 |
| 52 Week Low | US$3.10 |
| Beta | 4.02 |
| 1 Month Change | -22.43% |
| 3 Month Change | -21.50% |
| 1 Year Change | -69.71% |
| 3 Year Change | -39.81% |
| 5 Year Change | -98.75% |
| Change since IPO | -99.30% |
Recent News & Updates
Recent updates
Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding
Aug 29
Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities
Sep 26Exicure Q2 GAAP loss per share narrows, revenue up
Aug 15Exicure regains compliance with Nasdaq's minimum bid price requirement
Jul 20Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance
Jun 29Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?
Aug 25Shareholder Returns
| XCUR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.7% | -1.7% | 0.9% |
| 1Y | -69.7% | 27.7% | 28.2% |
Return vs Industry: XCUR underperformed the US Biotechs industry which returned 27.7% over the past year.
Return vs Market: XCUR underperformed the US Market which returned 28.2% over the past year.
Price Volatility
| XCUR volatility | |
|---|---|
| XCUR Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: XCUR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XCUR's weekly volatility has decreased from 16% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 8 | Jungsoo Kim | www.exicuretx.com |
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd.
Exicure, Inc. Fundamentals Summary
| XCUR fundamental statistics | |
|---|---|
| Market cap | US$20.65m |
| Earnings (TTM) | -US$4.95m |
| Revenue (TTM) | n/a |
Is XCUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XCUR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.95m |
| Earnings | -US$4.95m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.78 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XCUR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/04 21:25 |
| End of Day Share Price | 2026/05/04 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Exicure, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Keay Nakae | Chardan Capital Markets, LLC |
| Yatin Suneja | Guggenheim Securities, LLC |